Perspective Therapeutics, Inc. (CATX) FinancialsCATXPerspective Therapeutics, Inc.

Perspective Therapeutics, Inc. (CATX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Brachytherapy, accounting for 87.4% of total sales, equivalent to $1.91M. Another important revenue stream is Drug Operations. Understanding this composition is critical for investors evaluating how CATX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Perspective Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -36120.99%, while the net margin is -33312.35%. These profitability ratios, combined with a Return on Equity (ROE) of -39.57%, provide a clear picture of how effectively CATX converts its operational activities into shareholder value.

In the context of the broader market, CATX competes directly with industry leaders such as PROF and YDES. With a market capitalization of $363.00M, it holds a leading position in the sector. When comparing efficiency, CATX's gross margin of 100.00% stands against PROF's 78.41% and YDES's 28.05%. Such benchmarking helps identify whether Perspective Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of 100% consistently, but it is struggling with significant net losses, including -26,786,000 USD in Q2 2026. The total revenue has been declining, with Q2 2026 revenue at only 81,000 USD, down from previous quarters.